Genenta Science S.p.A. (GNTA)

IT — Healthcare Sector
Peers: MOLN  MNOV  ANEB  CSBR  CYT  PMVP  ELYM  PHVS  PEPG  MLYS  JANX  RZLT  GLSH  OPT  PRDS  ANTX  AVTE  ADAG 

Automate Your Wheel Strategy on GNTA

With Tiblio's Option Bot, you can configure your own wheel strategy including GNTA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol GNTA
  • Rev/Share 0.0
  • Book/Share 0.6845
  • PB 5.7313
  • Debt/Equity 0.0
  • CurrentRatio 6.894
  • ROIC -0.7427

 

  • MktCap 71749552.8026
  • FreeCF/Share -0.0003
  • PFCF -12617.9882
  • PE -8.0245
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.6089

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference
GNTA
Published: May 08, 2025 by: Newsfile Corp
Sentiment: Neutral

Milan, Italy and New York, New York--(Newsfile Corp. - May 8, 2025) - Genenta Science, SpA (NASDAQ: GNTA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.

Read More
image for news Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference
Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates
GNTA
Published: March 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

MILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing through the issuance of a Mandatory Convertible Bond to ENEA Tech and Biomedical (ETB) to support the expansion of its pipeline by advancing Temferon in metastatic Renal Cell Cancer (mRCC). ETB is a leading private foundation, supervised by the Italian Ministry of Enterprises and Made in Italy, managing over €1,7 billion in assets under management through two funds.

Read More
image for news Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

About Genenta Science S.p.A. (GNTA)

  • IPO Date 2021-12-15
  • Website https://www.genenta.com
  • Industry Biotechnology
  • CEO Mr. Pierluigi Paracchi
  • Employees 13
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.